Ist das Testosteron-Management beim fortgeschrittenen hormonsensitiven Prostatakarzinom zeitgemäß?

Zusammenfassung

Die hormonablative Therapie (ADT) ist beim fortgeschrittenen oder metastasierten Prostatakarzinom Standard. Hier wird sie entweder allein oder in Kombination mit weiteren Verfahren und Substanzen eingesetzt. Der Testosteron-Zielwert von < 50 ng/dl bzw. < 1.7 nmol/l wurde vor mehr als 40 Jahren willkürlich und sowie aufgrund, aus heutiger Sicht unsensibleren Messmethoden definiert. Seitdem sind immer mehr Daten generiert worden, die nahelegen, dass bei einem Testosteronwert < 20 ng/dl die Progression zum kastrationsresistenten Prostatakarzinom verzögert wird. Obwohl eine Absenkung des Zielwerts vielfach schon gefordert wird, hat dies noch keinen Eingang in die Praxis gefunden. Die Messung des Testosteronwerts zur Kontrolle des Ansprechens auf eine Hormonablation gehört bisher nicht zu den regulären Kontrolluntersuchungen. Auch in nationalen und internationalen Leitlinien gibt es hierzu keine konkreten Empfehlungen. Auf Basis der zunehmenden Evidenz rückt die Frage nach der klinischen Relevanz des Testosteron-Managements während der ADT immer stärker in den Fokus. Die aktuelle Datenlage hierzu soll in der vorliegenden Arbeit dargestellt werden.

Abstract

Androgen-deprivation therapy (ADT) is the standard therapy used for advanced or metastatic prostate cancer, either alone or in association with additional procedures and substances. The optimum value of testosterone postulated more than 40 years ago was arbitrarily set to be < 50 ng/dL or < 1.7 nmol/L and, from todayʼs perspective, was defined by more insensitive measurement methods. Since then, more and more data has been generated, suggesting that a value of < 20 ng/dL would be prognostically relevant. Yet no guideline has been changed so far despite the call for lowering the target value. Measuring testosterone to evaluate the response to androgen suppression is not yet established in clinical routine. There are no specific recommendations in national and international guidelines. Based on the evolving evidence, the question about testosterone management during ADT is gaining importance. The current data is summarised in this paper.

Schlüsselwörter

Monitoring - Testosteron - Prognose - Androgendeprivation - fortgeschrittenes Prostatakarzinom

Keywords

advanced prostate cancer - follow-up - androgen deprivation therapy - monitoring

Publication History

Received: 02 March 2021

Accepted after revision: 30 June 2021

Article published online:
23 September 2021

• Literatur

• 1 Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168: 9-12 DOI: 10.1016/s0022-5347(05)64820-3. (PMID: 12050481)
• 2 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021, AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
• 3 Shayegan B, Pouliot F, So A. et al. Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians. Can Urol Assoc J 2017; 11: 204-209 DOI: 10.5489/cuaj.4539. (PMID: 28652880)
• 4 Wheeler MJ, D'Souza A, Matadeen J. et al. Ciba Corning ACS:180 testosterone assay evaluated. Clin Chem 1996; 42: 1445-1449 (PMID: 8787702)
• 5 Pieczonka CM, Twardowski P, Renzulli 2nd J. et al. Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients. Rev Urol 2018; 20: 63-68 DOI: 10.3909/riu0798. (PMID: 30288142)
• 6 Twardowski P, Atkinson S, Boldt-Houle D. et al. Late dosing of luteinizing hormone-releasing hormone agonists (LHRH) and testosterone (T) levels >20 ng/dL in prostate cancer (PCa). Journal of Clinical Oncology 2020; 38: 31-31
• 7 Testa U, Castelli G, Pelosi E. Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines (Basel) 2019; 6 DOI: 10.3390/medicines6030082. (PMID: 31366128)
• 8 Oefelein MG, Feng A, Scolieri MJ. et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000; 56: 1021-1024 DOI: 10.1016/s0090-4295(00)00793-7. (PMID: 11113751)
• 9 Tombal B, Berges R. Optimal control of testosterone: A clinical case based approach of modern androgen-deprivation therapy. Eur Urol 2008; 7: 15-21
• 10 Bertaglia V, Tucci M, Fiori C. et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 2013; 11: 325-330.e321 DOI: 10.1016/j.clgc.2013.01.002. (PMID: 23531429)
• 11 Pickles T, Hamm J, Morris WJ. et al. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?. BJU Int 2012; 110: E500-507 DOI: 10.1111/j.1464-410X.2012.11190.x. (PMID: 22564197)
• 12 Morote J, Planas J, Salvador C. et al. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2009; 103: 332-335 DOI: 10.1111/j.1464-410X.2008.08062.x. (PMID: 19007366)
• 13 Morote J, Orsola A, Planas J. et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 1290-1295 DOI: 10.1016/j.juro.2007.05.129. (PMID: 17698136)
• 14 Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?. BJU Int 2010; 105: 648-651 DOI: 10.1111/j.1464-410X.2009.08814.x. (PMID: 19747358)
• 15 Hammerer P, Grohmann W, Merseburger AS. Current data on the target value of testosterone lowering and the associated research since the first administration of LHRH (GnRH) analogues to patients 40 years ago. 2020; DOI: 10.1055/a-1121-7400..
• 16 Klotz L, O'Callaghan C, Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015; 33: 1151-1156 DOI: 10.1200/JCO.2014.58.2973. (PMID: 25732157)
• 17 Crawford ED, Heidenreich A, Lawrentschuk N. et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 2019; 22: 24-38 DOI: 10.1038/s41391-018-0079-0. (PMID: 30131604)
• 18 Mottet N, Bellmunt J, Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017; 71: 618-629 DOI: 10.1016/j.eururo.2016.08.003. (PMID: 27568654)
• 19 Shore ND, Antonarakis ES, Cookson MS. et al. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate 2020; 80: 527-544 DOI: 10.1002/pros.23967. (PMID: 32130741)
• 20 Saad F, Fleshner N, Pickles T. et al. Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. J Urol 2020; 204: 416-426 DOI: 10.1097/JU.0000000000000809. (PMID: 32096678)
• 21 Lowrance WT, Breau RH, Chou R. et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol 2021; 205: 14 DOI: 10.1097/JU.0000000000001375. (PMID: 32960679)
• 22 Rüssel C. GnRH-Antagonisten in der Therapie des metastasierten Prostatakarzinoms. 2011 https://www.arzneimitteltherapiede/heftarchiv/2011/03/gnrh-antagonisten-in-der-therapie-des-metastasierten-prostatakarzinoms-stellenwert-von-degarelix-und-anwendung-in-der-praxis.html
• 23 Bundesinstitut für Arzneimittel und Medizinprodukte. Rote-Hand-Brief zu leuprorelinhaltigen Depotarzneimitteln: Notwendigkeit der genauen Einhaltung der Anweisungen bezüglich Zubereitung und Verabreichung zur Verringerung des Risikos von Anwendungsfehlern. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2020/rhb-leuprorelin.html 2020
• 24 Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther 2016; 9: 7263-7274 DOI: 10.2147/OTT.S117176. (PMID: 27942220)
• 25 Mottet N, Cornford P, van den Bergh E. et al. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. EAU Guidelines Office; Arnhem, The Netherlands: ISBN: 978-94-92671-13-4
• 26 Higano CS. Intermittent Versus Continuous Androgen Deprivation Therapy. JNCCN 2015; 12: 327-733
• 27 Tangen CM, Hussain MHA, Higano CS. et al. lmproved Overall 5urvival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A 5WOG Phase III Trial Experience (S8494, S8894 & S9346). J Urol 2012; 188: 1164-1169
• 28 Kamada S, Sakamoto S, Ando K. et al. Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade. J Urol 2015; 194: 1264-1270 DOI: 10.1016/j.juro.2015.03.120. (PMID: 25861958)